Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
Silvio Danese(IRCCS Ospedale San Raffaele), Wit Danilkiewicz, О. Б. Щукина(City Clinical Hospital No 31), Remo Panaccione(University of Calgary), Katarzyna Wójcik‐Pszczoła, Eran Zittan(Emek Medical Center), Walter Reinisch(Medical University of Vienna), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Monika Augustyn, Mary Ellen Frustaci(Johnson & Johnson (United States)), Martin Laclav, Zijiang Yang(Henan Medical University), Tomasz Arłukowicz, Ursula Seidler(Medizinische Hochschule Hannover), Dino Tarabar(Military Medical Academy), William J. Sandborn(University of San Diego), Rafał Filip(University of Rzeszów), Daphne Chan(Janssen (United States)), Tadakazu Hisamatsu(Kyorin University), Jane M. Andrews(Health Net), Laura Loy, Piotr Gietka, Julián Panés(Hospital Clínic de Barcelona), Tkachev Av(Rostov State Medical University), Shu‐Chen Wei(Kaohsiung Medical University), Slobodan Srećković, Juris Pokrotnieks(Pauls Stradiņš Clinical University Hospital), Brian G. Feagan(Western University), David T. Rubin(University of California System), Geert D’Haens(Amsterdam University Medical Centers), Leonid Bilіanskyi, A Borsuk, George Duvall, Niazy Abu-farsakh, Natalie A. Terry(Janssen (United States)), Jadwiga Gniady-Jastrzebska, Andro Machavariani, Aparna Sahoo(Otsuka (United States)), Douglas C. Wolf(Atlanta Gastroenterology Associates), Marcin Zmudziński, Syed Mumtaz, Xavier Hébuterne, Adi Lahat-Zok, Pesegova Marina, Oleksandr Oliinyk, Anita Afzali(University of Cincinnati Medical Center), Robert Petryka, Chenglong Han(Janssen (United States)), Carsten Büning(Charité - Universitätsmedizin Berlin), Daniel R. Suiter
Cited by 72
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k